NTLA
Intellia
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About NTLA
Intellia Therapeutics, Inc.
A leading developer of in vivo genome editing therapies using CRISPR technology
Biological Technology
Invalid Date
05/06/2016
NASDAQ Stock Exchange
403
12-31
Common stock
40 Erie Street
, Suite 130
, Cambridge
, Massachusetts 02139
--
Intellia Therapeutics, Inc., was incorporated in Delaware in May 2014. The company is a leading gene editing company focused on the development of unique, potentially curative therapies using a recently developed systematic biological tool known as CRISPR/Cas 9. The company believes that the CRISPR/Cas9 technology has the potential to modify drugs in the human body by permanently editing disease-associated genes with a single course of treatment. The company intends to use its leading scientific expertise, clinical development experience and intellectual property position to unlock the broad therapeutic applications of CRISPR/Cas9 gene editing and develop a new generation of therapeutic products with potential.
Company Financials
EPS
NTLA has released its 2024 Q4 earnings. EPS was reported at -1.27, versus the expected -1.32, beating expectations. The chart below visualizes how NTLA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NTLA has released its 2024 Q4 earnings report, with revenue of 12.87M, reflecting a YoY change of 771.57%, and net profit of -128.90M, showing a YoY change of 2.47%. The Sankey diagram below clearly presents NTLA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
